Form 4: Neogenomics CFO Jeffrey Scott Sherman Reports Stock Option Grant and RSU Vesting

Chief Financial Officer Jeffrey Scott Sherman reports the acquisition and disposal of Neogenomics stock and derivative securities, including the grant of stock options and restricted stock units (RSUs), as well as the vesting of previously granted RSUs.

Summary

• On February 23, 2025, Jeffrey Scott Sherman, CFO of Neogenomics Inc., reported transactions involving the company's stock.
• These transactions included the acquisition of 15,535 shares of common stock through the vesting of restricted stock units and the disposal of 4,207 shares to cover tax withholding obligations.
• Sherman also received a grant of 214,900 stock options and 126,476 restricted stock units on February 21, 2025, which vest ratably over three years.
• Following these transactions, Sherman directly owns 137,064 shares of Neogenomics common stock, 249,169 stock options granted on December 5, 2022, 73,016 stock options granted on May 11, 2023, 77,913 stock options granted on February 23, 2024, 214,900 stock options granted on February 21, 2025, 26,011 restricted stock units, 39,016 performance stock units, 59,382 restricted stock units, 46,606 performance stock units, and 31,071 restricted stock units.
• The stock options have exercise prices ranging from $11.62 to $19.65.
• The performance stock units vest based on the achievement of certain share growth and revenue growth goals.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The grants themselves are a positive sign of incentivizing management, but the filing itself doesn't indicate any major positive or negative developments for the company.

Positives

• The grant of stock options and RSUs to the CFO aligns his interests with those of shareholders, incentivizing him to improve company performance.
• The vesting schedules of the stock options and RSUs encourage long-term commitment from the CFO.
• The inclusion of performance stock units ties a portion of the CFO's compensation to specific company performance metrics, such as share growth and revenue growth.

Future Outlook

The vesting of stock options and restricted stock units is contingent upon continued service with the company.

Industry Context

Stock grants and options are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options and RSUs, are standard practice among publicly traded companies like Neogenomics to incentivize performance and retain key personnel.
• Companies such as Exact Sciences and Guardant Health also utilize similar equity-based compensation strategies for their executives.
• The vesting schedules and performance-based criteria associated with these grants are generally aligned with industry norms to promote long-term value creation.

Stakeholder Impact

• Shareholders may view the stock option and RSU grants as a positive sign, aligning management's interests with their own.
• Employees may see the grants as a reflection of the company's commitment to its leadership team.
• The transactions have no immediate impact on customers, suppliers, or creditors.

Key Dates